Lipella Pharmaceuticals (LIPO) Competitors $2.52 +0.03 (+1.20%) Closing price 04:00 PM EasternExtended Trading$2.48 -0.04 (-1.79%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LIPO vs. DRRX, SNYR, LGVN, CGTX, PULM, ELEV, PASG, CVM, GRCE, and LIANShould you be buying Lipella Pharmaceuticals stock or one of its competitors? The main competitors of Lipella Pharmaceuticals include DURECT (DRRX), Synergy CHC Corp. (Uplisting) (SNYR), Longeveron (LGVN), Cognition Therapeutics (CGTX), Pulmatrix (PULM), Elevation Oncology (ELEV), Passage Bio (PASG), CEL-SCI (CVM), Grace Therapeutics (GRCE), and LianBio (LIAN). These companies are all part of the "pharmaceutical products" industry. Lipella Pharmaceuticals vs. DURECT Synergy CHC Corp. (Uplisting) Longeveron Cognition Therapeutics Pulmatrix Elevation Oncology Passage Bio CEL-SCI Grace Therapeutics LianBio Lipella Pharmaceuticals (NASDAQ:LIPO) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends, media sentiment and community ranking. Does the MarketBeat Community prefer LIPO or DRRX? DURECT received 315 more outperform votes than Lipella Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Lipella Pharmaceuticals an outperform vote while only 61.24% of users gave DURECT an outperform vote. CompanyUnderperformOutperformLipella PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo VotesDURECTOutperform Votes31661.24% Underperform Votes20038.76% Do analysts prefer LIPO or DRRX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipella Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00DURECT 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals and insiders hold more shares of LIPO or DRRX? 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 28.0% of DURECT shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by company insiders. Comparatively, 3.2% of DURECT shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, LIPO or DRRX? Lipella Pharmaceuticals has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Comparatively, DURECT has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Does the media favor LIPO or DRRX? In the previous week, Lipella Pharmaceuticals and Lipella Pharmaceuticals both had 2 articles in the media. Lipella Pharmaceuticals' average media sentiment score of 1.22 beat DURECT's score of 0.94 indicating that Lipella Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipella Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DURECT 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation and earnings, LIPO or DRRX? Lipella Pharmaceuticals has higher earnings, but lower revenue than DURECT. DURECT is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLipella Pharmaceuticals$536.36K11.98-$4.62M-$4.72-0.53DURECT$2.03M8.86-$27.62M-$0.27-2.15 Is LIPO or DRRX more profitable? DURECT has a net margin of -198.58% compared to Lipella Pharmaceuticals' net margin of -882.82%. Lipella Pharmaceuticals' return on equity of -192.33% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets Lipella Pharmaceuticals-882.82% -192.33% -154.24% DURECT -198.58%-300.62%-65.17% SummaryLipella Pharmaceuticals beats DURECT on 8 of the 15 factors compared between the two stocks. Get Lipella Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIPO vs. The Competition Export to ExcelMetricLipella PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.42M$6.69B$5.47B$7.92BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.597.3222.5118.54Price / Sales11.98241.49397.62103.35Price / CashN/A65.8538.1834.62Price / Book0.586.486.734.25Net Income-$4.62M$143.41M$3.22B$248.18M7 Day Performance-2.33%2.30%1.58%1.25%1 Month Performance-1.95%7.14%4.05%3.76%1 Year Performance-56.68%-2.61%15.75%5.28% Lipella Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIPOLipella Pharmaceuticals2.4571 of 5 stars$2.52+1.2%N/A-57.3%$6.42M$536,357.00-0.594Upcoming EarningsPositive NewsGap UpDRRXDURECT0.8284 of 5 stars$0.74-1.0%N/A-37.5%$23.15M$2.03M-1.2180Upcoming EarningsShort Interest ↓Positive NewsSNYRSynergy CHC Corp. (Uplisting)3.5307 of 5 stars$2.68+7.6%$10.00+273.1%N/A$22.97M$34.83M0.0040News CoveragePositive NewsLGVNLongeveron2.5528 of 5 stars$1.52+4.1%$8.67+470.2%-1.8%$22.69M$2.39M-0.2420Positive NewsGap UpCGTXCognition Therapeutics3.6361 of 5 stars$0.36-2.4%$7.13+1,859.6%-77.6%$22.53MN/A-0.3720Upcoming EarningsShort Interest ↓News CoveragePULMPulmatrix0.822 of 5 stars$6.16-2.4%N/A+247.9%$22.48M$7.81M-2.3320Short Interest ↓Positive NewsELEVElevation Oncology2.4021 of 5 stars$0.38-2.0%$3.39+795.5%-89.5%$22.39MN/A-0.4640Gap UpPASGPassage Bio2.3092 of 5 stars$0.36+9.1%$7.50+1,983.3%-74.7%$22.37MN/A-0.31130CVMCEL-SCIN/A$0.26+2.5%N/A-80.1%$21.97MN/A-0.5443Analyst ForecastGRCEGrace Therapeutics2.3935 of 5 stars$2.15+2.9%$12.00+458.1%N/A$21.80MN/A-1.85N/APositive NewsGap UpLIANLianBioN/A$0.20flatN/A-41.5%$21.61MN/A-0.25110News CoverageGap Down Related Companies and Tools Related Companies DRRX Competitors SNYR Competitors LGVN Competitors CGTX Competitors PULM Competitors ELEV Competitors PASG Competitors CVM Competitors GRCE Competitors LIAN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIPO) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipella Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipella Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
